aTyr Pharma, Inc.
ATYR
$0.53
-$0.03-5.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 190.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 190.00K | -- | -- |
| Cost of Revenue | 7.32M | 10.89M | 22.13M | 15.38M | 11.81M |
| Gross Profit | -7.32M | -10.89M | -21.94M | -15.38M | -11.81M |
| SG&A Expenses | 4.12M | 3.91M | 4.81M | 4.93M | 3.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.44M | 14.80M | 26.94M | 20.31M | 15.77M |
| Operating Income | -11.44M | -14.80M | -26.75M | -20.31M | -15.77M |
| Income Before Tax | -10.79M | -13.96M | -25.75M | -19.53M | -14.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.79M | -13.96M | -25.75M | -19.53M | -14.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.00K | 1.00K | 2.00K | 1.00K | 1.00K |
| Net Income | -10.79M | -13.96M | -25.74M | -19.53M | -14.88M |
| EBIT | -11.44M | -14.80M | -26.75M | -20.31M | -15.77M |
| EBITDA | -11.27M | -14.63M | -26.58M | -20.15M | -15.61M |
| EPS Basic | -0.11 | -0.14 | -0.27 | -0.22 | -0.17 |
| Normalized Basic EPS | -0.07 | -0.09 | -0.17 | -0.14 | -0.11 |
| EPS Diluted | -0.11 | -0.14 | -0.27 | -0.22 | -0.17 |
| Normalized Diluted EPS | -0.07 | -0.09 | -0.17 | -0.14 | -0.11 |
| Average Basic Shares Outstanding | 98.04M | 98.01M | 97.15M | 90.12M | 86.49M |
| Average Diluted Shares Outstanding | 98.04M | 98.01M | 97.15M | 90.12M | 86.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |